Physician profile
Alexander Seng
NPI 1891340048
$19,199.12
in general payments reported to CMS, 2019-2025
38 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,123 · 2022: $4,962 · 2023: $5,094 · 2024: $3,190 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,858 · Consulting Fee: $150 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,858.30 |
| Consulting Fee | $150.00 |
| Education | $106.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,229.29 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $2,343.42 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $2,172.36 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $1,421.96 | 2021-2024 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $1,041.40 | 2021-2024 | Dupixent |
| Genzyme Corporation | $899.78 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $794.77 | 2021-2025 | Stiolto Respimat, Ofev, Spiriva Respimat |
| United Therapeutics Corporation | $694.39 | 2021-2024 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $495.85 | 2021-2024 | |
| Harmony Biosciences LLC | $472.93 | 2022-2025 | Wakix |
| Pfizer INC. | $449.74 | 2021-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $441.90 | 2024-2025 | Lumryz |
| Mylan Specialty L.P. | $407.39 | 2021-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $380.11 | 2021-2025 | Acthar |
| Philips North America LLC | $337.23 | 2021-2025 | Vest Therapy Und |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $337.01 | 2022-2025 | Tavneos, Tezspire |
| Dexcom, INC. | $222.42 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Baxter Healthcare | $207.50 | 2022-2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Carnation Ambulatory Monitor |
| Insmed, INC. | $206.78 | 2021-2023 | Arikayce |
| Axsome Therapeutics, INC. | $191.89 | 2022-2024 | Sunosi |
| Genentech USA, INC. | $189.59 | 2021-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $154.98 | 2022-2023 | |
| Verona Pharma, INC. | $124.50 | 2025 | Ohtuvayre |
| Insulet Corporation | $113.08 | 2025 | Omnipod |
| Novo Nordisk INC | $100.00 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2024 | Lifevest |
| Lilly USA, LLC | $99.18 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $98.28 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $83.34 | 2021-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $64.94 | 2021-2023 | Glassia |
| Teva Pharmaceuticals USA, INC. | $56.64 | 2021-2022 | |
| Inspire Medical Systems, INC. | $47.86 | 2023-2025 | Inspire |
| Advanced Respiratory, INC | $47.35 | 2021 | |
| Viatris Specialty LLC | $39.22 | 2025 | Yupelri |
| Electromed, INC. | $37.97 | 2021 | |
| Ani Pharmaceuticals, INC. | $36.68 | 2022-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $35.97 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.42 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Seng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.